{ "docId": "019de071-c3db-754b-ac24-62da0106c648", "docSlug": "d868b21c892e5009b811b85948ad2b78", "documentTitle": "Ginkgo | Results Presentation Deck | 36 slides", "authorId": "ginkgo", "authorName": "Ginkgo Bioworks", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "pageCount": 36, "prevPage": 19, "nextPage": 21, "slideType": "other", "function": "illustrate_case", "density": "overcrowded", "nDataPoints": 0, "notes": "The slide uses a case study approach to highlight business model flexibility.", "elementsJson": null, "metadataConfidence": 0.9, "imagePath": null, "slideHref": "/slides/019de071-c3db-754b-ac24-62da0106c648/20", "deckHref": "/decks/019de071-c3db-754b-ac24-62da0106c648", "deckJsonHref": "/decks/019de071-c3db-754b-ac24-62da0106c648.json", "deckAnchorHref": "/decks/019de071-c3db-754b-ac24-62da0106c648#slide-20", "components": [ { "bbox": { "h": 0.08, "w": 0.32, "x": 0.04, "y": 0.18 }, "kind": "callout", "text": "Large or Mid-sized Companies", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e1bfda47-6ead-462e-b667-70b6b55191ea", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.22, "y": 0.6 }, "kind": "image", "text": "Cronos Group", "attrs": null, "subkind": "logo", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "25900f42-6663-4fb3-ae02-a79206344e2a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.34, "y": 0.85 }, "kind": "image", "text": "Givaudan", "attrs": null, "subkind": "logo", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9911bf12-70e4-4532-88d9-b10569c4445b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.05, "y": 0.38 }, "kind": "image", "text": "Aldevron", "attrs": null, "subkind": "logo", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a3997ad6-cae0-4213-8d2c-625b72228ce2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.04, "y": 0.7 }, "kind": "list", "text": "Customer pays Ginkgo for Foundry services (variety of models)\nDownstream value primarily structured with milestones and royalties", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a872b20d-79a2-4c77-8797-31e93310212f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.51, "y": 0.35 }, "kind": "paragraph", "text": "Ginkgo subsidized R&D as part of pro bono COVID response, with royalty on sales", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "2e57f6b3-cb34-43dc-8cf0-f739d936c95c", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.28, "x": 0.19, "y": 0.33 }, "kind": "paragraph", "text": "In the News: Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "50e8ff41-ba35-431c-b7a5-2d5fb805f1e7", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.28, "x": 0.49, "y": 0.83 }, "kind": "paragraph", "text": "Ginkgo Bioworks and Givaudan Enter Multi-Program Collaboration to Produce a Series of Ingredients", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "65030beb-0e71-4a38-ade6-b1cfc2c7b3b1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.79, "y": 0.85 }, "kind": "paragraph", "text": "Collaboration with a balance of service fees and downstream value", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "812d3410-7994-489c-8f43-ffcda898a06e", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.67, "y": 0.58 }, "kind": "paragraph", "text": "Flat R&D fee plus technical and commercial milestones", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "88c68497-1c16-4dc7-a889-a9294cdf8761", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.1, "w": 0.3, "x": 0.33, "y": 0.57 }, "kind": "paragraph", "text": "Cronos Group Launches its First Cultured Cannabinoid Product, SPINACH FEELZ™ Chill Bliss 2:1 THC|CBG Gummy", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f79aadd8-8de8-46f8-be01-099ad48f374d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.75, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "Our flexibility in business model is important, even for our largest customers", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3806ff4a-cfe9-4091-be3b-92af8e4d9ade", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Audience frame", "slug": "audience-frame", "agent": null, "layer": "slide", "matchId": "306628b9-9672-48a0-bdb7-83a99dc6fb3c", "evidence": "Our flexibility in business model is important, even for our largest customers", "confidence": 0.7 }, { "name": "Story Moments", "slug": "story-moments", "agent": "Storyteller", "layer": "slide", "matchId": "3c65d47b-d222-479e-9cdf-5c24f9cce15e", "evidence": "Collaboration with a balance of service fees and downstream value", "confidence": 0.5 } ], "frameworks": [], "arcBeats": [ { "to": 22, "from": 17, "beatId": "04c9d655-8324-4493-8ee0-0c1211b161f5", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "The Breakthrough", "beatSlug": "rags-to-riches-the-breakthrough", "evidence": "The deck discusses the company's approach to investing in and subsidizing startup partners", "position": 3, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "loops": [ { "to": 22, "from": 17, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "dadbc662-3d20-40f2-a3e1-3ccbd3306cdf", "evidence": "The deck implies that not investing in the company's platform would lead to missed opportunities", "position": 2, "objective": "To discuss the consequences of not investing in the company's platform", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }